The scientific and technological advances that enable targeted disruption of stratum corneum while protecting deeper tissues have brought the field to a new level of capabilities that position trans-dermal drug delivery for increasingly widespread impact on medicine.
Tangible Coating for Comfortable Application
Release of Natural Ingredients
External Coating for Action that Lasts
“Transdermal patches or transdermal therapeutic systems (TTS) are SUBSTANCES delivery systems that are applied directly to the skin. The active substance is absorbed by the skin and distributed through the body via the bloodstream. This innovative mode of administration has improved the simplicity of treatment for patients for almost 30 years… “
Just Peel and Stick!
Remove & Repeat
The patch as a therapeutic system (TTS)
The patch as a therapeutic system
Transdermal patches or transdermal therapeutic systems (TTS) are SUBSTANCES delivery systems that are applied directly to the skin. The active substance is absorbed by the skin and distributed through the body via the bloodstream. This innovative mode of administration has improved the simplicity of treatment for patients for almost 30 years.
Some of the major advantages that the patch is able to offer is the user never has to remember when he took a pill, wafer, candy or potion. The patch goes to work automatically while the user lives a normal life, even if they travel a lot, works different shifts, sleeps late or is busy night and day raising a family. The ingredients are released into the skin over a timed release through absorption.
The application of medications to the skin to ease ailments is a practice that has been utilized by humankind over the millennia and has included the application of poultices, gels, ointments, creams, and pastes. These applications were primarily intended for a local topical effect.
The use of adhesive skin patches to deliver drugs systemically is a relatively new phenomenon.
History of the patch
The first adhesive transdermal delivery system (TDDS) patch was approved by the Food and Drug Administration in 1979 (scopolamine patch for motion sickness). Nitroglycerine patches were approved in 1981. This method of delivery became widely recognized when nicotine patches for smoking cessation were introduced in 1991.
TDDS offer pharmacological advantages over the oral route and improved patient acceptability and compliance. As such, they have been an important area of pharmaceutical research and development over the last few decades.
There are a number of advantages associated with transdermal drug delivery. With this route of administration, it is possible to avoid pain and presystemic metabolism. In addition, pharmacokinetic profile of the drug is more uniform with fewer peaks and troughs. However, the outermost layer of the skin. the stratum corneum. constitutes a strong barrier making it difficult for permeants to cross the skin at clinically relevant rates. This review examines progress made over the last 4 decades and challenges ahead. Over this period, about 35 transdermal products have been approved by regulatory authorities. About 19 drugs have been formulated into transdermal patches and approved by the Food and Drug Administration. The main challenge lies with the formulation of macromolecules- proteins, small interfering RNA and other products of biotechnology into transdermal delivery systems. This challenge is being met with approaches such as microneedles, iontophoresis, sonophoresis and electroporation.
Overall, transdermal drug delivery offers compelling opportunities to address the low bioavailability of many oral drugs; the pain and inconvenience of injections; and the limited controlled release options of both. Building off the successes of first-generation transdermal patches, second-generation chemical enhancers and iontophoresis are expanding delivery capabilities for small molecules, whereas third-generation physical enhancers (including ultrasound, thermal ablation and microneedles) could enable transdermal delivery of macromolecules and vaccines. These scientific and technological advances that enable targeted disruption of stratum corneum while protecting deeper tissues have brought the field to a new level of capabilities that position transdermal drug delivery for increasingly widespread impact on medicine.
- Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery, Nat Rev , 2004, vol. 3 (pg. 115-24)
- Journal of Drug Delivery Science and Technology, Volume 24, Issue 3, 2014, Pages 245-250